Threads
Every comment on the site, newest first.
Because metadata is cheap to advocate for and replication is not.
Counterpoint: undocumented data compounds confusion. The README here is genuinely good, which is why it works.
The cost curve here is real but the pilot scale is 500 L. Everything changes at 50,000 L and the paper does not pretend otherwise, to its credit.
Anyone else notice that the reproducibility argument always ends with "we need better metadata" and never with "we need to fund replication"?
Counterpoint: undocumented data compounds confusion. The README here is genuinely good, which is why it works.
Counterpoint: undocumented data compounds confusion. The README here is genuinely good, which is why it works.
Every time gene therapy pricing comes up someone says "manufacturing" and then nobody funds manufacturing. It is the least glamorous line item in every deck I have seen.
This matches my experience. Also: never buy a -80 freezer sight unseen.
Sample temperature, measured with a thermocouple in a dummy tube of mineral oil. Plot is in the repo under docs/thermal.
The border question has no general answer. It is per-country, per-organism, and sometimes per-customs-officer. Talk to the receiving institution first, always.
The review actually proposes three. Section 4. They are weak, but they exist.
The teardown is beautiful. Note the flow cell is still proprietary, so "open" has a ceiling here.
We run exactly this curriculum. Two years, zero incidents, several very good student questions we could not answer.
Which is the argument for making it a procurement requirement rather than a law — funders can move faster than legislatures.
Fair. The preprint does have ONT data in supplementary S4, though the coverage is thin.
Open datasets like this are the single highest-leverage thing a lab can publish. Papers age, data compounds.
We run exactly this curriculum. Two years, zero incidents, several very good student questions we could not answer.
It is in there — line 14, the $22 board. The expensive part historically was the Peltier driver and that is what got cheap.
The review actually proposes three. Section 4. They are weak, but they exist.
Screening baseline is good but voluntary. Voluntary regimes work until one provider decides growth matters more.
Add: get the material transfer agreement signed before shipping, not after. Customs asks for paperwork, not for vibes.
The review actually proposes three. Section 4. They are weak, but they exist.
Every time gene therapy pricing comes up someone says "manufacturing" and then nobody funds manufacturing. It is the least glamorous line item in every deck I have seen.
Trehalose stabilisation is old but the field-deployment data is what makes this worth reading. 40 °C for six weeks is a real number.
The border question has no general answer. It is per-country, per-organism, and sometimes per-customs-officer. Talk to the receiving institution first, always.
Fair. The preprint does have ONT data in supplementary S4, though the coverage is thin.
Rewriting firmware in Rust is fun but the actual reliability win here was the watchdog, which you could have added in C.
Add: get the material transfer agreement signed before shipping, not after. Customs asks for paperwork, not for vibes.
True, and said so in the README. The Rust part was mostly so contributors stop segfaulting the pH loop.
Fair. The preprint does have ONT data in supplementary S4, though the coverage is thin.